Skip to main content

Table 2 Cyclin D1 and Ki67 immunolabelling in the histological variants of Thyroid neoplasm

From: Clinical impact of a cytological screening system using cyclin D1 immunostaining and genomic analysis for the diagnosis of thyroid nodules

 

Percentage of Cyclin D1

Percentage of Ki67

Variants of Thyroid neoplasm

Immunolabelled tumor cells (%)

Immunolabelled tumor cells (%)

MSR

Mean ± SD

PPV

MSR

Mean ± SD

PPV

(Range)

(Range)

Papillary thyroid carcinoma (n = 59)

48.5

42.9 ± 19.1

91.5

3.5

5.2 ± 5.7

76.3

(6.1–76.7)

(0.2–37.4)

Medullary thyroid carcinoma (n = 1)

66.4

66.4

100

4

4

11.1

Follicular carcinoma (n = 9)

34.2

36.0 ± 26.6

77.8

2.4

4.5 ± 6.1

28.6

(5.8–76)

(0.9–20.3)

Poorly differentiated thyroid carcinoma (n = 7)

45.9

42.3 ± 21

85.7

4.1

5.4 ± 4.2

60

(2.8–68.1)

(0.3–12.2)

Well differentiated tumor-uncertain malignant potential (n = 2)

41.5

41.5 ± 3.2

100

3.15

3.2 ± 2.9

50

(39.2–43.7)

(1.1–5.2)

Follicular adenoma (n = 7)

13.1

17.5 ± 15.3

66.7

2.3

2.9 ± 1.9

20

(2.5–43.2)

(1–6.8)

Anaplastic thyroid carcinoma (n = 5)

9.9

17.2 ± 19.5

33.3

10.4

8.3 ± 3.5

66.7

(1.9–49.7)

(4.4–11.7)

Background (inflammation or adenomatous goiter, n = 12)

3.4

3.4 ± 0.9

 

3.05

3.7 ± 1.4

 

(2.1–5.2)

(2.1–7.2)

  1. *MSR Medisan stain ratio, PPV Positive predictive value